WIRE — Capricor Therapeutics shares surged 94% intraday after the FDA indicated it was willing to review additional data for deramiocel, its experimental Duchenne muscular dystrophy treatment.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.